Upgrade to SI Premium - Free Trial

Mizuho Securities Upgrades Amedisys (AMED) to Buy; Pay Up for Strong Management

May 3, 2017 7:30 AM
Mizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $65.00.Analyst Sheryl Skolnick is positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Upgrades

Next Articles